Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-03-12

Clinical Trial Update: A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial compared CP-690,550 (tofacitinib) with tacrolimus in kidney transplant patients, with results posted after completion in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CP-690,550 (tofacitinib)
  • Tacrolimus (Tacrolimus)

Snippet

Sponsor: Pfizer | Conditions: Kidney Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2013-03-12